Irvine-based medical device maker enVVeno Medical Corp. today announced that it has regained compliance with the Nasdaq’s minimum bid price requirement.
The company, which is focused on making treatments for deep venous disease, said that it achieved the minimum $1 closing bid for 10 consecutive business days, and as a result, “the matter is now closed.”
In October, the company received a notification of non-compliance and was given 180 days, or until April 6, to regain compliance. Most recently, the board approved a 1 for 35 reverse stock split of its common stock that took effect on Jan. 20.
The company also reported cash and investments of approximately $28 million as of the year ended Dec. 31, 2025.
